Deferred Systemic Therapy Reasonable for Selected Renal Cell Carcinoma Patients

Share this content:
Delaying use of new targeted therapies may result in improved quality of life without adversely affecting outcomes.
Delaying use of new targeted therapies may result in improved quality of life without adversely affecting outcomes.

Deferred systemic therapy is a reasonable option for selected patients with metastatic renal cell carcinoma (mRCC), according to researchers. This approach may offer patients a better quality of life without negatively affecting survival.

Investigators at Duke University in Durham, NC, led by Daniel J. George, MD, reviewed data from 60 patients with mRCC who did not receive systemic therapy within the first year after diagnosis.1

Patients had a median age of 61.2, and their median duration from diagnosis of localized RCC to development of mRCC was 41.9 months.

Of these patients, 36 (60%) were managed with surgical metastasectomy alone, 7 patients (12%) received multiple local treatment modalities, 8 patients (13%) underwent active surveillance, 4 patients (7%) were managed supportively, and 5 patients (8%) were categorized as “other.”

The cohort had a median follow-up of 52.9 months. The 3-year survival was 83% overall and 94% for patients who underwent surgical metastasectomy as the initial management strategy.

At 3 years, 49% of patients had no evidence of disease and 19% had died or been transitioned to hospice. The 5-year survival rate was 59%, and 24% still had no evidence of disease.

RELATED: For Renal Cell Carcinoma, Combo Therapy as Effective as Bevacizumab Monotherapy

“Although the new targeted therapies for mRCC are better tolerated than systemic chemotherapies, they still have serious side effects,” the authors wrote. “Therefore, a strategy of delaying therapy may result in significant quality of life gains for these patients.”

In a discussion of study limitations, Dr. George's group pointed out that their cohort included only patients treated at a large academic medical center, so their sample may not be representative of all patients with mRCC or clinical environments because of sample bias and self-selection bias.

Mounting Evidence

The study adds to a growing body of evidence suggesting that deferred systemic therapy may be an attractive option for selected patients.1

Investigators at the University of Ulsan College of Medicine in Seoul, South Korea, studied 58 patients with asymptomatic or minimally symptomatic mRCC placed on active surveillance.2

After a median follow-up of 31.4 months, the median time to progression (the primary endpoint of the study) was 12.4 months, and the median overall survival was not reached.

“Asymptomatic or minimally symptomatic mRCC patients can be observed for a prolonged period without active treatment,” the researchers concluded.

Dr. George's team cited a report showing that, in a trial of pazopanib for mRCC, researchers observed no difference in overall survival between patients started immediately on the drug and those started on placebo who then transitioned to pazopanib only after disease progression.3

In a separate retrospective study of 62 patients with mRCC with asymptomatic or slow progressive disease, British researchers found that a period of observation prior to starting first-line therapy did not adversely affect progression-free and overall survival.4

After an average of 18.7 months of observation, 39 patients started on sunitinib, 18 patients were treated with interferon, and 5 received other agents. The median progression-free survival (PFS) among patients receiving first-line therapy was 9 months.

It was also 9 months for the group of patients who received sunitinib and it was 6.7 months for interferon recipients.

Median overall survival—defined as the time from the start of first-line therapy to death—was 25.2 months for all patients, 17.4 months for the sunitinib-treated patients, and 37.6 months for patients in the interferon group.

The authors stated that the median PFS and overall survival times were comparable to those observed in the pivotal phase 3 and expanded access trials of sunitinib.

Dr. George and his colleagues commented in their report, “In a time of quickly evolving treatment choices for patients with mRCC, it is critical that we understand treatment patterns and outcomes in routine clinical practice. The need to better understand the observed practice of delayed systemic therapy for patients with mRCC is such an example.”1  

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters